MABWELL-B

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical company that researches, develops, manufactures, and commercializes biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. Its marketed products include MAIWEIJIAN for giant cell tumor of bone, MALISHU for postmenopausal osteoporosis, MAILISHENG (albipagrastim alfa injection), and JUNMAIKANG (an autoimmune Adalimumab injection). The pipeline includes oncology candidates such as 9MW2821 (a Nectin-4 targeting drug in Phase III for cervical cancer), 7MW3711 (a B7-H3 targeting ADC for advanced malignant solid tumors), and 7MW4911 (an ADC targeting CDH17), as well as immunology candidates 9MW1911 (anti-ST2 antibody in Phase I for COPD) and 9MW3811 (anti-IL-11 antibody in Phase I). Other programs include 1MW5011 (oral tablet for osteoarthritis), ophthalmology candidates 9MW0813 (recombinant VEGF receptor-antibody fusion protein for vascularization-related ocular diseases) and 9MW0211 (recombinant anti-VEGF humanized monoclonal antibody injection in Phase III for neovascular eye diseases such as neovascular age-related macular degeneration), and hematology candidate 9MW3011 (recombinant humanized anti-TMPRSS6 monoclonal antibody in Phase I for polycythemia vera and iron overload disorders including beta-thalassemia). The company was founded in 2017 and is headquartered in Shanghai, China.